Drug Profile
Mometasone/olopatadine - Glenmark Pharmaceuticals
Alternative Names: GSP 301-1 NS; GSP 301-2 NS; GSP-301; Mometasone furoate/olapatadine hydrochloride; Olopatadine/mometasone; RYALTRIS; RyaltrisLatest Information Update: 08 May 2023
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Anti-inflammatories; Antiallergics; Antihistamines; Dibenzoxepins; Glucocorticoids; Pregnadienediols; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinitis; Perennial allergic rhinitis; Seasonal allergic rhinitis
Most Recent Events
- 03 May 2023 Launched for Seasonal allergic rhinitis (In adolescents, In children, In adults) in Canada (Intranasal)
- 10 Feb 2023 Launched for Allergic rhinitis in South Korea (Intranasal), prior to February 2023
- 23 Sep 2022 Registered for Seasonal allergic rhinitis (In adolescents, In adults, In children) in Canada (Intranasal)